RxDoctor Payments Data

Edward Washington

Glaucoma Specialist · Norcross, GANPI 1104211283

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,479 of the $1,688 with a category attached, or 87.6%. 10 manufacturers reported payments, led by Alcon at 28.2% of the total. Reporting peaked in 2022 at $700 and has fallen 50.6% since, to $346 in 2023.

$1,688in general payments, 2019–2025

Across 28 payments — averaging $60.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$476
  • AbbVie$346
  • Glaukos Corporation$236
  • NEW World Medical,inc.$192
  • Sight Sciences, Inc.$177
  • Alimera Sciences, Inc.$134
  • plus $126 from 4 others

What the payments were for

  • Food & beverage$1,47988%
  • Education$20912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$7,092
Medicare patients
18
Services billed
60

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate20$13,256
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat158$4,125
Latanoprost256$3,244
Brimonidine Tartrate117$1,810
Travoprost16$1,547
Prednisolone Acetate25$1,221
Timolol Maleate82$1,184
Dorzolamide Hcl28$759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa$19$13,25620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Norcross

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →